Drug Trial Radar · NCT05121038
CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
Last checked: Nov 19, 2026Latest source record: Dec 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Oct 20, 2021
Primary completion
Sep 2025
Study completion Sep 2026
Sponsor
- Lead sponsor
- Anup KasiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cend Therapeutics Inc.
- First posted
- Nov 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase IB/IIA trial to ensure the safety of Certepetide (LSTA1/CEND-1) in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers
Conditions
- Colon Cancer
- Pancreas Cancer
- Digestive Cancer
Interventions
CEND-1Drug
The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4).
PanitumumabDrug
Up to ten (10) participants with cancer that has spread to certain areas of the body and who have a certain gene in the tumor called "RAS/BRAF wild type" will receive another drug called panitumumab in addition to CEND-1 and FOLFIRINOX.
FolfirinoxDrug
FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order. All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle). * Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then * Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours. * Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours. then • Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Drug Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0Time frame: 24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
The University of Kansas Cancer Center (KUCC)
Fairway, Kansas
The University of Kansas Cancer Center, Westwood Campus
Kansas City, Kansas
The University of Kansas Medical Center
North Kansas City, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.